docetaxel SR

all catalysts(0)

nothing on the calendar yet

News(10)

• GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
  A phase 3 trial has linked GSK’s risvutatug rezetecan to a 67% reduction in the risk of disease progression or death, providing evidence that B7-H3-directed antibody-drug conjugates work in relapse…
  fiercebiotech · 1d ago
• ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
  At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.
  biopharma_dive · 1d ago
• ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
  Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its BioNTech-partnered PD-L1xVEGF-A drug are “very promising,” as phase 3 ambitions ram…
  fiercebiotech · 2d ago
• ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
  Roche has shed more light on its investigational KRAS G12C inhibitor’s phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati.
  fiercebiotech · 4d ago
• Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
  Looking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.
  fiercebiotech · 14d ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 1mo ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 1mo ago
• Pfizer punts Seagen ADC, further muddying value of the $43B buyout
  The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…
  biospace · 1mo ago
• RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
  The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall re…
  biospace · 1mo ago
• GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
  We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
  onclive · 5mo ago